Effect of the Cannabinoid Agonist WIN 55,212-2 on Neuropathic and Visceral Pain Induced by a Non-Diarrheagenic Dose of the Antitumoral Drug 5-Fluorouracil in the Rat

[thumbnail of ijms-24-14430.pdf]
Preview
ijms-24-14430.pdf - Published Version (7MB) | Preview
Available under license: Creative Commons Attribution

Vera, Gema, López-Gómez, Laura ORCID: 0000-0001-7352-5703, Girón, Rocío ORCID: 0000-0001-8530-8378, Martín-Fontelles, María Isabel, Nurgali, Kulmira ORCID: 0000-0002-2597-6929, Abalo, Raquel ORCID: 0000-0002-6726-8795 and Uranga, Jose A ORCID: 0000-0003-4656-8569 (2023) Effect of the Cannabinoid Agonist WIN 55,212-2 on Neuropathic and Visceral Pain Induced by a Non-Diarrheagenic Dose of the Antitumoral Drug 5-Fluorouracil in the Rat. International Journal of Molecular Sciences, 24 (19). ISSN 1422-0067

Abstract

5-fluorouracil (5-FU) is an antineoplastic drug used to treat colorectal cancer, but it causes, among other adverse effects, diarrhea and mucositis, as well as enteric neuropathy, as shown in experimental animals. It might also cause neuropathic pain and alterations in visceral sensitivity, but this has not been studied in either patients or experimental animals. Cannabinoids have antimotility and analgesic effects and may alleviate 5-FU-induced adverse effects. Our aim was to evaluate the effects of the cannabinoid agonist WIN 55,212-2 on neuropathic and visceral pain induced by a non-diarrheagenic dose of 5-FU. Male Wistar rats received a dose of 5-FU (150 mg/kg, ip) and gastrointestinal motility, colonic sensitivity, gut wall structure and tactile sensitivity were evaluated. WIN 55,212-2 (WIN) was administered to evaluate its effect on somatic (50–100 µg ipl; 1 mg/kg, ip) and visceral (1 mg/kg, ip) sensitivity. The cannabinoid tetrad was used to assess the central effects of WIN (1 mg/kg, ip). 5-FU decreased food intake and body weight gain, produced mucositis and thermal hyperalgesia, but these effects were reduced afterwards, and were not accompanied by diarrhea. Tactile mechanical allodynia was also evident and persisted for 15 days. Interestingly, it was alleviated by WIN. 5-FU tended to increase colonic sensitivity whereas WIN reduced the abdominal contractions induced by increasing intracolonic pressure in both control and 5-FU-treated animals. Importantly, the alleviating effects of WIN against those induced by 5-FU were not accompanied by any effect in the cannabinoid tetrad. The activation of the peripheral cannabinoid system may be useful to alleviate neuropathic and visceral pain associated with antitumoral treatment.

Dimensions Badge

Altmetric Badge

Item type Article
URI https://vuir.vu.edu.au/id/eprint/47201
DOI 10.3390/ijms241914430
Official URL https://www.mdpi.com/1422-0067/24/19/14430
Subjects Current > FOR (2020) Classification > 3214 Pharmacology and pharmaceutical sciences
Current > Division/Research > Institute for Health and Sport
Keywords pain, cannabinoid, neuropathic pain, visceral pain, laboratory rat
Download/View statistics View download statistics for this item

Search Google Scholar

Repository staff login